Skip to main content
. 2024 Nov 8;27(12):111344. doi: 10.1016/j.isci.2024.111344

Figure 2.

Figure 2

Predicted AMD progression and incidence according to the lipid-lowering drug and the CFH rs1061170 genotype

(A) Predicted AMD progression in Singapore Epidemiology of Eye Diseases (SEED) study according to the lipid-lowering drug (LLD) and the CFH rs1061170 genotype.

(B) Predicted AMD incidence in UK Biobank populations according to the LLD and the CFH rs1061170 genotype. The points represent the mean predicted progression rate (SEED) or incidence rate (UKBB), with the vertical bars indicating their 95% confidence intervals. Predictions from the UK Biobank were multiplied by 100 to facilitate the reading. These predictions were calculated using the LLD effects estimated from the multivariable models (as shown in Figure 1) using the inverse treatment probability weighting approach, and applied to the untreated population (see STAR Methods for details).